DrugBank
DrugBank is a Canadian biomedical data platform that provides an AI-ready, expert-curated knowledgebase of drugs, targets, diseases, and trials to biopharma enterprises, healthcare software integrators, and 1,500+ academic research institutions globally.
- Company typePrivate
- Founded2005
- HeadquartersEdmonton, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What DrugBank does
DrugBank is a Canadian biomedical data platform headquartered in Edmonton, Alberta, that operates an expert-curated, ontology-mapped knowledgebase connecting drugs, targets, diseases, clinical trials, and companies. Originating from the University of Alberta's Wishart Research Group, the platform has accumulated twenty years of continuous curation and is cited in 58,000+ peer-reviewed publications, used by 1,500+ academic institutions and 12M+ global users across 24+ countries, and licensed by 13+ top pharmaceutical companies including Bayer, Servier, Nippon Shinyaku, NIH, Healx, and Molecular Health.
The product architecture centers on the Biopharma Intelligence Operating System, an AI-powered intelligence layer for R&D, portfolio, and business development teams. It is complemented by the DrugBank Model Context Protocol (MCP) integration for AI research workflows, a Clinical Intelligence API for embedding drug search, drug-drug interaction, allergy, and label data into healthcare software, and a Data Library of AI/ML-ready datasets distributed via direct license and Snowflake Marketplace. The platform supports use cases spanning drug discovery and repurposing, translational medicine, competitive intelligence, and asset evaluation for in-licensing.
Revenue is generated primarily through subscription-based licensing across four streams: commercial enterprise licensing, accessible-rate academic licensing, Clinical Intelligence API subscriptions for healthcare software integrators, and data packages. Go-to-market combines direct enterprise field sales (with prominent "Book a Demo" and "Contact Sales" CTAs) for biopharma accounts with API-first and MCP-based distribution for technical and clinical software integrations. The company employs 11–50 staff and has raised approximately USD 7–8 million across pre-seed through seed and grant rounds, with Brightspark Ventures as lead seed investor.
DrugBank firmographics
Firmographics- Name
- DrugBank
- Legal name
- DrugBank
- Website
- https://drugbank.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DrugBank is a Canadian biomedical data platform that provides an AI-ready, expert-curated knowledgebase of drugs, targets, diseases, and trials to biopharma enterprises, healthcare software integrators, and 1,500+ academic research institutions globally.
- Ownership category
- akta.pro rank
DrugBank industry classification
Industry- Product category
- Biopharma Intelligence Software
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where DrugBank is headquartered
LocationHeadquarters
- HQ city
- Edmonton
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
DrugBank business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Commercial Licensing: DrugBank generates revenue through commercial licensing of its biomedical knowledgebase to pharmaceutical companies, biotech firms, and healthcare technology companies. Use or redistribution of DrugBank content or data requires a license and proper citations.
- Academic Licensing: DrugBank offers accessible-rate academic licenses for non-commercial research to academic institutions and research organizations worldwide.
- Clinical API Access: Revenue generated through Clinical Intelligence API subscriptions for healthcare software companies integrating drug information into their platforms.
- Data Packages and Professional Services: Data Library products and potentially professional services supporting research and drug discovery applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Commercial Enterprise License - Enterprise-level access for biopharma companies |
| Subscription | Annual | Academic License - Accessible-rate licensing for academic and non-commercial research |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
DrugBank product offering
Product offeringCore offering
DrugBank operates an AI-powered biopharma intelligence platform built on a gold-standard, expert-validated biomedical knowledgebase that connects drugs, targets, diseases, trials, and companies. Its core deliverables include the Biopharma Intelligence Operating System, a Clinical Intelligence API for healthcare software integration, DrugBank MCP for AI workflow integration, AI/ML-ready ontology-mapped datasets, and accessible academic licensing for non-commercial research.
Product overview
DrugBank offers a unified platform architecture centered on the Biopharma Intelligence Operating System, which serves as the AI-powered backbone for biopharma connecting drugs, targets, diseases, trials, and companies. The core offering is supplemented by the DrugBank MCP for AI workflow integration, a Clinical Intelligence API for healthcare software integration, and a Data Library of AI/ML-ready datasets. The platform also includes specialized solutions for Business Development & Licensing and Drug Discovery & Repurposing use cases, with accessible academic licenses available for non-commercial research.
Differentiator
Problem solved
Functional benefit
Products and services
- Biopharma Intelligence Operating System AI-powered intelligence platform enabling critical research decisions for R&D, portfolio, and strategy teams. Connects scientific depth with commercial context to guide teams from data to decision across drug discovery, competitive intelligence, and translational medicine use cases.
- Clinical Intelligence API API for integrating comprehensive evidence-based drug information into healthcare software, including drug search, drug-drug interaction checking, drug allergy identification, and US drug labels. Used by telehealth providers, EMR systems, and clinical decision support platforms.
- DrugBank MCP Model Context Protocol integration enabling trusted biomedical intelligence directly into AI research workflows. Allows access to DrugBank data within AI assistant platforms and AI-driven R&D processes.
- Data Library Detailed drug information packages supporting research and drug discovery, including ontology-mapped, AI/ML-ready datasets for integration into customer proprietary platforms and machine learning models.
- Academic Data Access Accessible-rate academic licenses for non-commercial research. Used by 1,500+ research institutions and cited in 58,000+ publications, providing comprehensive biomedical knowledge to power academic research.
- Drug Knowledgebase Comprehensive database of drug information including drug profiles, pathways, drug reactions, drug classification, drug targets, target sequences, spectra search, pharmaco-omics, and chemical structure search. Underpins the Biopharma Intelligence Operating System, Clinical Intelligence API, and Data Library.
Quantifiable outcome
- Trusted by 13+ top pharmaceutical companies in over 24 countries
- +3 more outcomes
Companies that use DrugBank
Customer profileNamed customers7 records
Segments8 records
Ideal customer profiles3 records
DrugBank technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability7 records
Feature5 records
DrugBank partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- DistillerSR / Eureka-ITEA Research ConsortiumcoreDrugBank is a collaborator in the three-year Eureka-ITEA research consortium, a six-country international R&D network representing 45 countries. The consortium, led by DistillerSR, includes collaborators such as Philips Medical Systems and University of Leiden Medical Center. DrugBank contributes to the Smart Evidence Extraction module using purpose-built GenAI to extract evidence from scientific literature at scale.
- EvE BiocoreEvE Bio and DrugBank partnered to integrate EvE Bio's comprehensive pharmome-mapping data into DrugBank's platform. EvE Bio's dataset includes over 385,000 drug-protein interactions, surpassing previous public benchmarks. The integration enhances drug-target interaction insights for drug discovery and supports applications such as drug repurposing and off-target liability exploration.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
DrugBank competitors and assessment
Company assessmentBroad incumbents
- Clarivate: Clarivate operates Cortellis and Drug360, broad life-sciences intelligence platforms covering drug, clinical-trial, patent, and commercial data. It is comparable to DrugBank as an enterprise biopharma intelligence vendor, but with a significantly wider portfolio and installed base.
- Elsevier (Reaxys / Embase / PharmaPendium): Elsevier offers Reaxys for chemistry/drug data, Embase for biomedical literature, and PharmaPendium for regulatory drug information. It overlaps DrugBank's drug and target knowledgebase scope but within a much larger scientific publishing and data portfolio.
- IQVIA: IQVIA combines clinical trial operations, real-world evidence, and commercial intelligence for life sciences. It competes with DrugBank in biopharma intelligence but on a much larger scale, with deep clinical and commercial data assets.
- Springer Nature (AdisInsight): Springer Nature's AdisInsight provides drug development, clinical trial, and pharmacovigilance intelligence. It competes with DrugBank's intelligence offering, particularly around competitive landscape and pipeline monitoring, as part of a broader academic publishing business.
Direct peers
- Citeline (Informa Pharma Intelligence): Citeline provides drug pipeline, clinical trial, and competitive intelligence products (e.g., Trialtrove, Pharmaprojects) directly comparable to DrugBank's competitive and landscape intelligence modules, serving the same biopharma enterprise buyers.
- BenchSci: BenchSci applies AI to biomedical literature and experiment data to help scientists select reagents and design experiments. It is directly comparable to DrugBank as an AI-powered biomedical research data platform serving pharma R&D teams.
Emerging players
- OpenTargets: OpenTargets is a public-private partnership providing target-disease association evidence for drug discovery. It is comparable to DrugBank's target and disease intelligence modules but operates as a non-profit/open consortium rather than a commercial platform.
- Owkin: Owkin builds AI-native biopharma data and model infrastructure (e.g., Owkin Studio, MOSAIQ). It overlaps DrugBank's positioning as an AI/biopharma data layer but extends further into proprietary model development and clinical decision support.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
DrugBank social profiles
Digital presenceDrugBank financial estimates
Financial estimateRevenue estimate
Valuation estimate
DrugBank leadership team
Management profileNumber of profiles
Profiles3 records
DrugBank funding detail
Funding detailFunding overview
Funding rounds7 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DrugBank M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DrugBank
What does DrugBank do?
DrugBank operates an AI-powered biopharma intelligence platform built on a gold-standard, expert-validated biomedical knowledgebase that connects drugs, targets, diseases, trials, and companies. Its core deliverables include the Biopharma Intelligence Operating System, a Clinical Intelligence API for healthcare software integration, DrugBank MCP for AI workflow integration, AI/ML-ready ontology-mapped datasets, and accessible academic licensing for non-commercial research.
Is DrugBank a public or private company?
DrugBank is a private company. It is classified as venture growth investor backed and is currently operating.
When was DrugBank founded?
DrugBank was founded in 2005. It employs 11 to 50 people.
Where is DrugBank based?
DrugBank is headquartered in Edmonton, Canada, in the North America region.
How does DrugBank make money?
Four revenue lines are on record. Commercial Licensing is the primary driver. The others are academic Licensing, clinical API Access and data Packages and Professional Services.
Who are DrugBank's main competitors?
Broad incumbents on record are Clarivate, Elsevier (Reaxys / Embase / PharmaPendium), IQVIA and Springer Nature (AdisInsight). Direct peers are Citeline (Informa Pharma Intelligence) and BenchSci. Emerging players are OpenTargets and Owkin.
Does DrugBank have an API?
Yes. DrugBank offers a Clinical Intelligence API that enables developers to integrate comprehensive evidence-based drug information into healthcare software applications. The API supports drug search, drug-drug interaction checking, drug allergy identification, and US drug label access. Additional API access is available for AI workflows via MCP (Model Context Protocol) integration.
What industry is DrugBank in?
DrugBank's product category is Biopharma Intelligence Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 621511.